Released : May 26, 2020 16:22 RNS Number : 9750N MaxCyte, Inc. 26 May 2020 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a.
Released : May 26, 2020 15:45 RNS Number : 9712N MaxCyte, Inc. 26 May 2020 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a.
Released : May 21, 2020 13:50 RNS Number : 6557N MaxCyte, Inc. 21 May 2020 THIS ANNOUNCEMENT IS RESTRICTED AND NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES (OR TO ANY US PERSON), CANADA , AUSTRALIA , JAPAN OR THE REPUBLIC
Released : May 14, 2020 07:00 RNS Number : 8406M MaxCyte, Inc. 14 May 2020 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte to Present Poster Presentation on MCY-M11 at ASCO 2020 Annual Meeting Gaithersburg, Maryland - 14 May 2020: MaxCyte (LSE: MXCT), the global clinical-stage
Released : May 07, 2020 07:00 RNS Number : 1970M MaxCyte, Inc. 07 May 2020 FOR IMMEDIATE RELEASE Caribou Biosciences and MaxCyte Enter into Clinical and Commercial License Agreement - Agreement enables Caribou to utilize MaxCyte's ExPERT® platform for
Released : May 01, 2020 07:00 RNS Number : 5828L MaxCyte, Inc. 01 May 2020 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES (OR TO ANY US PERSON), CANADA , AUSTRALIA , JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER
Released : April 30, 2020 17:39 RNS Number : 5668L MaxCyte, Inc. 30 April 2020 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES (OR TO ANY US PERSON), CANADA , AUSTRALIA , JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER
Released : April 21, 2020 07:00 RNS Number : 2678K MaxCyte, Inc. 21 April 2020 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte Reports Final Results for Year Ended 31 December 2019 Gaithersburg, Maryland - 21 April 2020: MaxCyte (LSE: MXCT), the global clinical-stage cell-based
Released : April 09, 2020 07:00 RNS Number : 2917J MaxCyte, Inc. 09 April 2020 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte Provides Business Update Related to COVID-19 Pandemic - Robust start to trading year with strong revenue results year-to-date 2020 - Dosing of fourth
Released : March 24, 2020 07:00 RNS Number : 2942H MaxCyte, Inc. 24 March 2020 FOR IMMEDIATE RELEASE MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement · Agreement enables Allogene, a pioneer in the development of
